Topical alprostadil and a clitoral vacuum pump, two new treatments for female sexual arousal disorder (FSAD) presented on May 25 at the American Urological Association annual meeting, improved sexual response by increasing genital blood flow.
“Female sexual dysfunction (FSD) is very common, occurring in 20-50% of the general population, while one survey indicates that 20% of adult women have FSAD,” lead author Marc Gittelman, MD, from Uro-medix in Miami, Florida, says in a news release.
“To date, there are no FDA-approved pharmacological treatments for this disorder, but topical alprostadil may be an appropriate on-demand treatment for women suffering from FSAD.”
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!